Biology subjects

Cesnarikova, S.

Publications and source records attributed to Cesnarikova, S..

4 recordsLinked to original sources

bioRxiv2026

Patient-Derived PSEN1 Cerebral Organoids Revealed Parallel Development of Amyloid-β Accumulation and Network Dysfunction

Alzheimers disease (AD) is a neurodegenerative disorder characterised by progressive dementia, brain atrophy, and ultimately death. Using cerebral organoids derived from human induced pluripotent stem cells (hiPSCs) carrying the familial PSEN1 A246E variant, we investigated the temporal relationship between amyloid-{beta} (A{beta}) dysregulation and spontaneous neuronal activity. Multielectrode array recordings from the differentiation day 60 (DD60) to at least DD130 revealed that AD organoids exhibited transient hyperexcitability and hypersynchrony compared with wild-type (WT) controls, followed by a gradual decline in activity. During the enhanced excitability stage, both elevated A{beta}42/40 and A{beta} aggregate size showed positive correlations with the percentage of active electrodes and the global synchrony index (GSI) in AD organoids. These findings indicate that A{beta} dysregulation might contribute to transient network hyperexcitability in early AD. The results also suggest that patient-derived cerebral organoids may serve as a translational model to examine early network dysfunction and inform future investigations of potential A{beta}-induced changes in excitability during the preclinical stages of AD.

neuroscience↗

bioRxiv2025

Soluble SORL1 in cerebrospinal fluid as a marker for functional impact of rare SORL1 variants.

BackgroundAs part of the retromer, sortilin-related receptor (SORL1) sorts cargo proteins away from the endosome to the trans-Golgi network or to the cell surface, where SORL1 is cleaved into sSORL1 and shed into the interstitial fluid and CSF. SORL1s cargo includes APP and A{beta}, which may explain why protein-truncating genetic variants (PTVs) in SORL1 are observed almost exclusively in Alzheimers Disease (AD) patients, and that rare, predicted pathogenic missense variants have been associated with a 10-fold increased risk of AD. However, functional evidence supporting variant pathogenicity is warranted. Here we investigated whether soluble SORL1 (sSORL1) concentrations in cerebrospinal fluid (CSF) offer a potential in vivo biomarker to support impaired SORL1 function in variant carriers. MethodsUsing an ELISA assay for SORL1 (ABCAM), we determined sSORL1 concentrations in CSF from 218 participants of the Alzheimer Dementia Cohort (ADC) (54% females). We compared sSORL1 in CSF derived from 90 carriers of diverse SORL1 variants with concentrations observed in 78 SORL1-WT AD patients, and 50 SORL1-WT controls for whom CSF-pTau-181, CSF-tTau, CSF-A{beta}42 concentrations were available. In a subset of 36 individuals, we used Western blotting (WB) to validate sSORL1 concentrations as determined by ELISA. ResultsCSF-sSORL1 concentrations did not differ between SORL1-WT AD patients and controls. While CSF-sSORL1 did not correlate with CSF-A{beta}42 concentrations in SORL1-WT AD patients (p=0.62), it correlated with sCSF-ptau-181 (p=9.7x10-6). The mean CSF-sSORL1 concentration in the SORL1 WT AD cases and controls was 466 pg/ml, with wide variance (SD = 133). Comparatively, concentrations were significantly lower in PTV carriers (260 pg/ml, p=3.2x10-7) and in carriers of predicted damaging SORL1 missense variants (323 pg/ml, p=2.4x10-7). CSF-sSORL1 concentrations measured by ELISA correlated strongly with concentrations estimated by WB ({rho}=0.552; p=5.0x10-4). ConclusionCSF-sSORL1 increases with CSF-ptau, suggesting that increased SORL1-retromer activity may serve to rescue cellular stress associated with AD-related processes. However, impairing SORL1 genetic variants may preclude SORL1 trafficking to the cell surface, as supported by lower CSF-sSORL1 protein concentrations in carriers. While further refinements are necessary, we present first evidence for the applicability of ELISA-based quantification of sSORL1 in CSF to evaluate the functional impact of rare SORL1 variants.

neuroscience↗

bioRxiv2025

The Alzheimer's-Associated SORL1 p.Y1816C Variant Impairs APP Sorting, Axonal Trafficking, and Neuronal Activity in iPSC-Derived Brain Models

BackgroundSORL1, encoding the sorting receptor SORLA, is now recognized as the fourth autosomal dominant Alzheimers disease (AD) gene. Loss of SORLA function is known to disrupt endosomal trafficking and enhance amyloidogenic APP processing, two key aspects of the onset and progression of AD. However, the pathogenic consequences of disrupted endolysosomal pathways, deregulated protein sorting, as well as the effects of specific SORL1 missense variants on human neuronal function, still remain understudied. MethodsOur investigations were performed using two complementary human iPSC-derived models: 2D NGN2-induced neurons and 3D cerebral organoids established from isogenic wild-type (WT), SORL1 p.Y1816C (KI) missense variant, and SORL1 knock-out (KO) cells. We analyzed SORLA maturation and ectodomain shedding, APP localization, and amyloid-{beta} secretion. Endosomal morphology and neuritic swellings were assessed via electron microscopy, while axonal transport of APP and Rab5+ endosomes was evaluated through live-cell imaging. Neuronal network activity was measured using multielectrode array recordings. ResultsOur results demonstrate that the p.Y1816C variant leads to impaired SORLA maturation and reduced shedding, without affecting neuronal or organoid differentiation. Notably, we show an ultrastructure of endosomes, including their content, and demonstrate that both KO and KI models exhibit early endosome enlargement, increased APP retention in endosomes, elevated A{beta}40/42 secretion, and amyloid-{beta} deposition in 3D organoids. Importantly, we identified previously uncharacterized functional consequences of abolished SORLA activity, including axonal swellings and significantly impaired transport of Rab5+ endosomes and APP, characterized by deregulated velocities, directionality of transport, and increased stalling. Additionally, we discovered that both KO and p.Y1816C KI neurons exhibit abnormal electrophysiological activity, including increased spontaneous firing, burst frequency, and network synchrony. ConclusionsOur study defines the mechanistic consequences of the SORL1 p.Y1816C variant and demonstrates its pathogenicity in human neurons. Importantly, we also identify novel roles for SORLA in maintaining axonal transport homeostasis and regulating neuronal excitability, expanding its functional relevance beyond endosomal APP processing. These findings reinforce the central role of endosomal trafficking disruption in AD and support the use of isogenic human models for evaluating AD risk variants.

neuroscience↗

bioRxiv2025

Viral Infection Induces Alzheimer's Disease-Related Pathways and Senescence in iPSC-Derived Neuronal Models

Structured AbstractO_ST_ABSINTRODUCTIONC_ST_ABSThe Pathogen Infection Hypothesis proposes that {beta}-Amyloid (A{beta}) functions as an antimicrobial peptide, with pathogen-induced aggregation potentially contributing to Alzheimers disease (AD) pathology. METHODSWe used human iPSC-derived 2D neurons and 3D cerebral organoids from wild-type and familial AD (PSEN1/2 mutant) lines to model acute infections with HSV-1 and TBEV and A{beta} aggregation. Transcriptomic and proteomic analyses were conducted to assess molecular responses. RESULTSHSV-1, but not TBEV, induced robust A{beta} clustering, which was, however, dependent on extracellular amyloid peptides. Transcriptomic profiling revealed widespread HSV-1-induced changes, including activation of neurodegeneration-related pathways. Proteomic profiling confirmed enrichment of neurodegeneration- and senescence-associated secretome signatures. PSEN1/2 mutations did not alter the acute infection response. Reanalysis of independent datasets confirmed our findings and revealed a limited protective effect of acyclovir. DISCUSSIONResults directly support the Pathogen Infection Hypothesis and suggest that preventing viral infections via vaccinations may represent a feasible approach to reducing AD risk.

neuroscience↗